MX362239B - Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales. - Google Patents

Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.

Info

Publication number
MX362239B
MX362239B MX2015016083A MX2015016083A MX362239B MX 362239 B MX362239 B MX 362239B MX 2015016083 A MX2015016083 A MX 2015016083A MX 2015016083 A MX2015016083 A MX 2015016083A MX 362239 B MX362239 B MX 362239B
Authority
MX
Mexico
Prior art keywords
inhibitor
retinochoroidal
disorders
retinochoroidal disorders
atrophy
Prior art date
Application number
MX2015016083A
Other languages
English (en)
Other versions
MX2015016083A (es
Inventor
Kimura Kazuhiro
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of MX2015016083A publication Critical patent/MX2015016083A/es
Publication of MX362239B publication Critical patent/MX362239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/08—Protective covers for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se dirige al problema de proporcionar un inhibidor para trastornos retinocoroidales, en particular, un inhibidor para formación de cicatrices retinocoroidales y atrofia retinocoroidal en un tejido epiretinal, intraretinal o subretinal. Este problema se puede resolver al preparar un inhibidor para trastornos retinocoroidales que comprende, como un ingrediente activo, ácido (E)-4-(2-{3-[(1H-pyrazol-1-il)metil]-5,5 ,8,8-tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico, un éster del mismo o una sal del mismo. El inhibidor para trastornos retinocoroidales puede inhibir la atrofia de colágeno de las células epiteliales pigmentarias retinales, fibroblastos, células gliales y similares y de esta manera inhibe los trastornos retinocoroidales.
MX2015016083A 2013-05-22 2014-05-21 Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales. MX362239B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013107706 2013-05-22
PCT/JP2014/002667 WO2014188716A1 (ja) 2013-05-22 2014-05-21 網脈絡膜障害の抑制剤

Publications (2)

Publication Number Publication Date
MX2015016083A MX2015016083A (es) 2016-03-21
MX362239B true MX362239B (es) 2019-01-09

Family

ID=51933283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016083A MX362239B (es) 2013-05-22 2014-05-21 Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.

Country Status (22)

Country Link
US (3) US10702502B2 (es)
EP (2) EP3446690B1 (es)
JP (2) JP6407145B2 (es)
KR (1) KR102303316B1 (es)
CN (1) CN105377258B (es)
AU (1) AU2014269762B2 (es)
BR (1) BR112015029114B1 (es)
CA (1) CA2913005C (es)
CY (1) CY1121036T1 (es)
DK (1) DK3000466T3 (es)
ES (1) ES2694831T3 (es)
HK (1) HK1221909A1 (es)
HR (1) HRP20181876T1 (es)
LT (1) LT3000466T (es)
MX (1) MX362239B (es)
PL (1) PL3000466T3 (es)
PT (1) PT3000466T (es)
RS (1) RS58045B1 (es)
RU (1) RU2672057C2 (es)
SI (1) SI3000466T1 (es)
WO (1) WO2014188716A1 (es)
ZA (1) ZA201508940B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
CN105188753B (zh) 2012-11-08 2018-12-18 国立大学法人山口大学 角结膜病症的治疗剂
KR102303316B1 (ko) * 2013-05-22 2021-09-23 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 망막 맥락막 장해의 억제제
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
EP3541380B1 (en) 2016-11-16 2021-12-15 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (mo)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2139063T3 (es) * 1993-01-11 2000-02-01 Ligand Pharm Inc Compuestos que tienen selectividad por receptores de retinoides x.
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
JP2003526677A (ja) 2000-03-14 2003-09-09 ザ・ユニバーシテイ・オブ・ウエスタン・オンタリオ 骨形成に影響を与える組成物および方法
AU2001289913B2 (en) 2000-10-02 2006-08-17 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
BR0212607A (pt) 2001-09-18 2004-08-17 Hoffmann La Roche Agonistas retinóides ii de uréia substituìda
EP1430024A1 (en) 2001-09-18 2004-06-23 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
KR20070121758A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 면역 억제 화합물의 주사가능한 조성물
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
US20090281184A1 (en) 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
KR20070037188A (ko) 2005-09-30 2007-04-04 현대자동차주식회사 자동 변속기에서 유량 제어구조
BRPI0709886A2 (pt) * 2006-03-31 2011-07-26 Hoffmann La Roche processo para a preparaÇço de compostos retinàides
EP2026778B1 (en) 2006-05-16 2018-11-14 Io Therapeutics, LLC Rar antagonist or inverse agonist for use in the treatment of chemotherapy and/or radiation therapy side effects
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
EP2089023A2 (en) * 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
CA2812952A1 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
CN105188753B (zh) 2012-11-08 2018-12-18 国立大学法人山口大学 角结膜病症的治疗剂
KR102303316B1 (ko) * 2013-05-22 2021-09-23 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 망막 맥락막 장해의 억제제

Also Published As

Publication number Publication date
PL3000466T3 (pl) 2019-04-30
US20160120843A1 (en) 2016-05-05
US20240180873A1 (en) 2024-06-06
PT3000466T (pt) 2018-11-27
JP2018115221A (ja) 2018-07-26
SI3000466T1 (sl) 2019-02-28
KR102303316B1 (ko) 2021-09-23
US11730718B2 (en) 2023-08-22
CN105377258A (zh) 2016-03-02
CN105377258B (zh) 2020-08-28
EP3446690A1 (en) 2019-02-27
JPWO2014188716A1 (ja) 2017-02-23
RS58045B1 (sr) 2019-02-28
LT3000466T (lt) 2019-02-11
AU2014269762B2 (en) 2019-09-12
US10702502B2 (en) 2020-07-07
JP6749962B2 (ja) 2020-09-02
US20210121442A1 (en) 2021-04-29
EP3000466A4 (en) 2017-01-25
ZA201508940B (en) 2017-11-29
EP3000466A1 (en) 2016-03-30
HK1221909A1 (zh) 2017-06-16
CA2913005A1 (en) 2014-11-27
BR112015029114B1 (pt) 2020-11-24
NZ715245A (en) 2021-04-30
AU2014269762A1 (en) 2016-01-07
MX2015016083A (es) 2016-03-21
CY1121036T1 (el) 2019-12-11
HRP20181876T1 (hr) 2019-03-08
RU2672057C2 (ru) 2018-11-09
EP3446690B1 (en) 2024-09-11
BR112015029114A2 (pt) 2017-07-25
ES2694831T3 (es) 2018-12-27
CA2913005C (en) 2021-08-10
JP6407145B2 (ja) 2018-10-17
DK3000466T3 (en) 2018-11-26
WO2014188716A1 (ja) 2014-11-27
BR112015029114A8 (pt) 2020-03-17
EP3000466B1 (en) 2018-08-15
KR20160013075A (ko) 2016-02-03
RU2015154741A (ru) 2017-06-28

Similar Documents

Publication Publication Date Title
MX362239B (es) Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.
EP3646851A4 (en) ANTI-AGING COMPOSITION WITH LACTIC ACID BACTERIA-DERIVED EXTRACELLULAR VESICLES
EP3357500A4 (en) COMPOSITION FOR PREVENTING HAIR LOSS OR FOR PROMOTING HAIR GROWTH WITH EXTRACELLULAR FOLLICLES FROM MILK ACID BACTERIA
EP3409213A4 (en) NEW SUTURE WIRE FOR FACE LIFTING AND BODY LIFTING
EP2996172A3 (en) Biocompatibility of biomedical energization elements
MY189172A (en) Herbicidal composition comprising cinmethylin and specific quinolinecarboxylic acids
EA026931B9 (ru) Гербицидно и фунгицидно действующие 5-оксизамещенные 3-фенилизоксазолин-5-карбоксамиды и 5-оксизамещенные 3-фенилизоксазолин-5-тиоамиды или их соли
WO2016044229A3 (en) Safened herbicidal compositions comprising pyridine carboxylic acids
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
PH12017501409A1 (en) Substituted 2-thiomidazolyl-carboxamides as pest control agents
CA3060354A1 (en) Compositions and methods for controlling strong acid systems
MY179287A (en) Methods for control of aquatic weeds using herbicidal 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acids
MX2015013229A (es) Control de malezas sinergisticoa partir de aplicaciones de penoxsulam y petoxamida.
SA113340735B1 (ar) تركيبات مبيدة للأعشاب مؤمِّنة تتضمن حمض 4 - أمينو-3- كلورو-5-فلورو-6-(4 - كلورو-2- فلورو-3- ميثوكسي فينيل) بيريدين-2- كربوكسيلي أو مشتق منه وطرق لاستخدامها
EP2685627A3 (en) Voltage increasing control circuit and power tool
EP3533346A4 (en) COMPOSITION COMPRISING PURIFIED CHLOROGENIC ACIDS
WO2016071362A3 (en) Herbicidal compounds
PH12018501695A1 (en) Substituted -oxyimidazolyl-carboxamides as pest control agents
EP3409291A4 (en) TRANSDERMAL ABSORBABLE COMPOSITION WITH CONTROLLED RELEASE OF A WATER SOLUBLE ACTIVE ACTIVE SUBSTANCE
EP3421041A4 (en) COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISORDERS COMPRISING EXOPOLYSACCHARIDE PRODUCING LEUCONOSTOC MESENTEROIDES AS ACTIVE INGREDIENTS
EP2696362A3 (de) Steuervorrichtung für ein Schaltgerät mit getrennter Anzug- und Haltespule
PL3799567T3 (pl) Krople do oczu zawierające kwas cytrynowy jako jedyny aktywny składnik
EP3826547A4 (en) KNOTLESS TISSUE REPAIR
PL3619199T3 (pl) Wytwarzanie pochodnych kwasu 2-([1,2,3]triazol-2-ilo)­-benzoesowego
EP3530110A4 (en) SUBSTRATE FOR CONTROLLING FLIES AND OTHER INSECTS, METHOD OF MANUFACTURING THEREFORE AND USE OF THE SUBSTRATE AS AN ANIMAL BED

Legal Events

Date Code Title Description
FG Grant or registration